ReviewInternational journal of molecular sciences2023
Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor.Journal of veterinary internal medicine · 2026Article
- Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning models.NPJ precision oncology · 2026Article
- Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy.Dermatopathology (Basel, Switzerland) · 2025Review
- Pembrolizumab-Induced Hypothyroidism and Diabetes Mellitus: A Rare Case Presentation Post-Treatment.Cureus · 2025Article
- Recent advances in the investigation of the quinazoline nucleus and derivatives with potential anticancer activities.Future medicinal chemistry · 2025Review
- Advances in Melanoma and Skin Cancers.International journal of molecular sciences · 2025Article
- Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.International journal of molecular sciences · 2025Review
- Tracking temporal shifts of peripheral blood NLR, PLR, and ALB: a prognostic tool for PD-1 inhibitor efficacy in advanced malignant melanoma.Frontiers in oncology · 2025Article
- The role of antibody glycosylation in autoimmune and alloimmune kidney diseases.Nature reviews. Nephrology · 2024Review
- Editorial: Molecular genetics of cutaneous melanoma: current status and future direction-volume II.Frontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pembrolizumab has been shown to increase survival in patients with metastatic melanoma. Considering the numerous oncoming studies, we decided to conduct a narrative review of the latest efficacy evidence regarding the use of pembrolizumab, alone or in combination, in patients with metastatic melanoma. A search was conducted in PubMed using "pembrolizumab," and "metastatic melanoma" as keywords, considering studies from 2022 onward. We reviewed pembrolizumab and associations, cost-effectiveness, virus, advanced acral melanoma, long-term outcomes, real-life data, biomarkers, obesity, and vaccines. In conclusion, pembrolizumab is a fundamental option in the therapy of metastatic melanoma. However, a certain group of patients do not respond and, therefore, new combination options need to be evaluated. In particular, the use of vaccines tailored to tumor epitopes could represent a breakthrough in the treatment of resistant forms. Further studies with larger sample numbers are needed to confirm the preliminary results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.